Showing 1 - 7 results of 7 for search 'Koen de Heer', query time: 0.03s Refine Results
  1. 1
    Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia

    Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia by Raquel Delgado, Karoline Kielbassa, Johanna ter Burg, Christian Klein, Christine Trumpfheller, Koen de Heer, Arnon P. Kater, Eric Eldering

    Published 2021-06-01
    Get full text
    Article
  2. 2
    Validation of the Visual/Verbal Analogue Scale of Food Ingesta (Ingesta-VVAS) in Oncology Patients Undergoing Chemotherapy

    Validation of the Visual/Verbal Analogue Scale of Food Ingesta (Ingesta-VVAS) in Oncology Patients Undergoing Chemotherapy by Hanneke A. H. Wijnhoven, Loïs van der Velden, Carolina Broek, Marleen Broekhuizen, Patricia Bruynzeel, Antoinette van Breen, Nanda van Oostendorp, Koen de Heer

    Published 2022-08-01
    Get full text
    Article
  3. 3
    P1523: IMMUNOGENICITY OF THE 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE FOLLOWED BY THE 23-VALENT POLYSACCHARIDE VACCINE IN CHRONIC LYMPHOCYTIC LEUKEMIA

    P1523: IMMUNOGENICITY OF THE 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE FOLLOWED BY THE 23-VALENT POLYSACCHARIDE VACCINE IN CHRONIC LYMPHOCYTIC LEUKEMIA by Sabine Haggenburg, Hannah Garcia Garrido, Iris Kant, Hanneke van der Straaten, Fransien De Boer, Sabina Kersting, Djamila Issa, Doreen Te Raa, Hein Visser, Arnon Kater, Abraham Goorhuis, Koen De Heer

    Published 2023-08-01
    Get full text
    Article
  4. 4
    Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia

    Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia by Sabine Haggenburg, Hannah M. Garcia Garrido, Iris M. J. Kant, Hanneke M. Van der Straaten, Fransien De Boer, Sabina Kersting, Djamila Issa, Doreen Te Raa, Hein P. J. Visser, Arnon P. Kater, Abraham Goorhuis, Koen De Heer

    Published 2023-07-01
    Get full text
    Article
  5. 5
    P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.

    P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON... by Sabina Kersting, Mark-David Levin, Julie Dubois, Yvette van Norden, Johan Dobber, Yvonne Jauw, Anne-Marie van der Kevie-Kersemaekers, Clemens Mellink, Caspar Da Cunha-Bang, Leonie Van Desr Burg, Doreen Te Raa, Fransien de Boer, Jolanda Droogendijk, Cecile Idink, Koen De Heer, Marten Nijziel, Lidwine Tick, Inge Ludwig, Mathijs Silbermann, Aart Beeker, Mar Bellido, Ludo Evers, Gerben Zwezerijnen, Josée Zijlstra, Marcel Kap, Carsten Niemann, Arnon Kater

    Published 2023-08-01
    Get full text
    Article
  6. 6
    P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY

    P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE... by Kaz Groen, Claudia Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. van Kampen, Rineke B.L. Leys, Noortje Thielen, Matthijs Westerman, Ka-Lung Wu, Inge Ludwig, Djamila E. Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Niels W.C.J. van de Donk, Gert-Jan Timmers, Fransien de Boer, Lidwine W. Tick, Ellen van der Spek, Esther G.M. de Waal, Maaike Sohne, Pieter Sonneveld, Inger S. Nijhof, Saskia K. Klein, Mark-David Levin, Paula F. Ypma, Sonja Zweegman

    Published 2023-08-01
    Get full text
    Article
  7. 7
    Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context

    Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context by Kaz Groen, Claudia A.M. Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. van Kampen, Rineke B.L. Leys, Noortje Thielen, Matthijs Westerman, Ka-Lung Wu, Inge Ludwig, Djamila E. Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Gert-Jan Timmers, Fransien de Boer, Lidwine W. Tick, Annelies Verbrugge, Danny Buitenhuis, Sonia M. Cunha, Ellen van der Spek, Esther G.M. de Waal, Maaike Sohne, Pieter Sonneveld, Inger S. Nijhof, Saskia K. Klein, Niels W.C.J. van de Donk, Mark-David Levin, Paula F. Ypma, Sonja Zweegman

    Published 2023-09-01
    Get full text
    Article

Search Tools: